Indications
Therapeutic Asset Ratings
9,920 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Methylphenidate
Brain Hypoxia - Ischemia
Massachusetts General Hospital
P1
CC
(43)
Metoclopramide
Prostate Neuroendocrine Neoplasm
Novartis Pharmaceuticals
P1
CC
(43)
Mezigdomide
Acute Myeloid Leukemia With Mutated NPM1
Massachusetts General Hospital
P1
CC
(43)
MGC026
Castration-Resistant Prostate Carcinoma
MacroGenics
P1
CC
(43)
MGC026
Esophageal Squamous Cell Carcinoma
MacroGenics
P1
CC
(43)
mgc028
Lung Adenocarcinoma
MacroGenics
P1
CC
(43)
mgd024
CD4+/CD56+ Hematodermic Neoplasm
MacroGenics
P1
CC
(43)
mgd024
Acute Myeloid Leukemia
MacroGenics
P1
CC
(43)
mgd024
Lymphoid Leukemia
MacroGenics
P1
CC
(43)
mgd024
Hairy Cell Leukemia
MacroGenics
P1
CC
(43)
Mgta-117
Myelodysplastic Syndrome
Magenta Therapeutics, Inc.
P1
CC
(43)
Mib-626
Down Syndrome
Brigham and Women's Hospital
P1
CC
(43)
Micvotabart
Neoplasm
Pyxis Oncology, Inc
P1
CC
(43)
Midazolam
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
P1
CC
(43)
Midazolam
Glioma
Pfizer
P1
CC
(43)
Midazolam
Pancreatic Ductal Adenocarcinoma
Alterome Therapeutics, Inc.
P1
CC
(43)
Midazolam
Thyroid Cancer
Pfizer
P1
CC
(43)
Miglustat
Glycogen Storage Disease II
Amicus Therapeutics
P1
CC
(43)
Minnelide
Pancreatic Adenocarcinoma
Minneamrita Therapeutics LLC
P1
CC
(43)
Minocycline
Neuronitis
University of Cincinnati
P1
CC
(43)
Minocycline
Schizophreniform Disorder
Pakistan Institute of Living and Learning
P1
CC
(43)
Minocycline
Sickle Cell Disease
University of Cincinnati
P1
CC
(43)
Minoxidil
Inherited Disease Susceptibility
Duke University
P1
CC
(43)
Mir-126 Inhibitor Miristen
Acute Myeloid Leukemia
City of Hope Medical Center
P1
CC
(43)
Mirabegron
Polycystic Ovary Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
P1
CC
(43)
Showing 3326 to 3350 of 9,920 assets
Previous
Page 134 of 397
Next